High nontransferrin bound iron levels and heart disease in thalassemia major

Antonio Piga, Fiomena Longo, Lorena Duca, Simona Roggero, Tiziana Vinciguerra, Roberto Calabrese, Chaim Hershko, Maria Domenica Cappellini

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Although the presence of nontransferrin bound plasma Iron (NTBI) in transfusional iron overload is well documented, knowledge about its clinical significance Is limited. We assessed NTBI levels in a large and homogeneous series of thalassemia patients on regular transfusion and chelation and explored the hypothesis that NTBI levels may be associated with relevant clinical outcomes: in particular, heart disease. Among 174 patients with thaiassemia major and intermedia, we showed the presence NTBI in 145 of 174 or 83.3% of cases. NTBI levels correlated with transferrin saturation, age, and ALT, and not with serum ferritin or liver Iron concentrations. At a multiple regression analysis, transferrin saturation and heart disease but not age was independent predictors of NTBI. Patients with heart disease had NTBI levels significantly higher than those without. All patients with heart disease had transferrin saturation above 70%, and all were NTBI positive. Conversely, none of the patients without NTBI and/or with transferrin saturation less than 70% had preclinical or clinical heart disease. To our knowledge, this is the first documentation of a link between the presence of NTBI In thalassemic patients with transfusional Iron overload and heart disease. Further investigation from these preliminary findings may clarify whether NTBI assessment may have a role in evaluating the risks and optimizing treatment for transfusion-dependent patients.

Original languageEnglish
Pages (from-to)29-33
Number of pages5
JournalAmerican Journal of Hematology
Volume84
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

beta-Thalassemia
Heart Diseases
Iron
Transferrin
Iron Overload
Thalassemia
Ferritins
Documentation
Regression Analysis

ASJC Scopus subject areas

  • Hematology

Cite this

High nontransferrin bound iron levels and heart disease in thalassemia major. / Piga, Antonio; Longo, Fiomena; Duca, Lorena; Roggero, Simona; Vinciguerra, Tiziana; Calabrese, Roberto; Hershko, Chaim; Cappellini, Maria Domenica.

In: American Journal of Hematology, Vol. 84, No. 1, 01.2009, p. 29-33.

Research output: Contribution to journalArticle

Piga, A, Longo, F, Duca, L, Roggero, S, Vinciguerra, T, Calabrese, R, Hershko, C & Cappellini, MD 2009, 'High nontransferrin bound iron levels and heart disease in thalassemia major', American Journal of Hematology, vol. 84, no. 1, pp. 29-33. https://doi.org/10.1002/ajh.21317
Piga, Antonio ; Longo, Fiomena ; Duca, Lorena ; Roggero, Simona ; Vinciguerra, Tiziana ; Calabrese, Roberto ; Hershko, Chaim ; Cappellini, Maria Domenica. / High nontransferrin bound iron levels and heart disease in thalassemia major. In: American Journal of Hematology. 2009 ; Vol. 84, No. 1. pp. 29-33.
@article{fdd8d15d3e034944b7f367d2d2f7ca40,
title = "High nontransferrin bound iron levels and heart disease in thalassemia major",
abstract = "Although the presence of nontransferrin bound plasma Iron (NTBI) in transfusional iron overload is well documented, knowledge about its clinical significance Is limited. We assessed NTBI levels in a large and homogeneous series of thalassemia patients on regular transfusion and chelation and explored the hypothesis that NTBI levels may be associated with relevant clinical outcomes: in particular, heart disease. Among 174 patients with thaiassemia major and intermedia, we showed the presence NTBI in 145 of 174 or 83.3{\%} of cases. NTBI levels correlated with transferrin saturation, age, and ALT, and not with serum ferritin or liver Iron concentrations. At a multiple regression analysis, transferrin saturation and heart disease but not age was independent predictors of NTBI. Patients with heart disease had NTBI levels significantly higher than those without. All patients with heart disease had transferrin saturation above 70{\%}, and all were NTBI positive. Conversely, none of the patients without NTBI and/or with transferrin saturation less than 70{\%} had preclinical or clinical heart disease. To our knowledge, this is the first documentation of a link between the presence of NTBI In thalassemic patients with transfusional Iron overload and heart disease. Further investigation from these preliminary findings may clarify whether NTBI assessment may have a role in evaluating the risks and optimizing treatment for transfusion-dependent patients.",
author = "Antonio Piga and Fiomena Longo and Lorena Duca and Simona Roggero and Tiziana Vinciguerra and Roberto Calabrese and Chaim Hershko and Cappellini, {Maria Domenica}",
year = "2009",
month = "1",
doi = "10.1002/ajh.21317",
language = "English",
volume = "84",
pages = "29--33",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - High nontransferrin bound iron levels and heart disease in thalassemia major

AU - Piga, Antonio

AU - Longo, Fiomena

AU - Duca, Lorena

AU - Roggero, Simona

AU - Vinciguerra, Tiziana

AU - Calabrese, Roberto

AU - Hershko, Chaim

AU - Cappellini, Maria Domenica

PY - 2009/1

Y1 - 2009/1

N2 - Although the presence of nontransferrin bound plasma Iron (NTBI) in transfusional iron overload is well documented, knowledge about its clinical significance Is limited. We assessed NTBI levels in a large and homogeneous series of thalassemia patients on regular transfusion and chelation and explored the hypothesis that NTBI levels may be associated with relevant clinical outcomes: in particular, heart disease. Among 174 patients with thaiassemia major and intermedia, we showed the presence NTBI in 145 of 174 or 83.3% of cases. NTBI levels correlated with transferrin saturation, age, and ALT, and not with serum ferritin or liver Iron concentrations. At a multiple regression analysis, transferrin saturation and heart disease but not age was independent predictors of NTBI. Patients with heart disease had NTBI levels significantly higher than those without. All patients with heart disease had transferrin saturation above 70%, and all were NTBI positive. Conversely, none of the patients without NTBI and/or with transferrin saturation less than 70% had preclinical or clinical heart disease. To our knowledge, this is the first documentation of a link between the presence of NTBI In thalassemic patients with transfusional Iron overload and heart disease. Further investigation from these preliminary findings may clarify whether NTBI assessment may have a role in evaluating the risks and optimizing treatment for transfusion-dependent patients.

AB - Although the presence of nontransferrin bound plasma Iron (NTBI) in transfusional iron overload is well documented, knowledge about its clinical significance Is limited. We assessed NTBI levels in a large and homogeneous series of thalassemia patients on regular transfusion and chelation and explored the hypothesis that NTBI levels may be associated with relevant clinical outcomes: in particular, heart disease. Among 174 patients with thaiassemia major and intermedia, we showed the presence NTBI in 145 of 174 or 83.3% of cases. NTBI levels correlated with transferrin saturation, age, and ALT, and not with serum ferritin or liver Iron concentrations. At a multiple regression analysis, transferrin saturation and heart disease but not age was independent predictors of NTBI. Patients with heart disease had NTBI levels significantly higher than those without. All patients with heart disease had transferrin saturation above 70%, and all were NTBI positive. Conversely, none of the patients without NTBI and/or with transferrin saturation less than 70% had preclinical or clinical heart disease. To our knowledge, this is the first documentation of a link between the presence of NTBI In thalassemic patients with transfusional Iron overload and heart disease. Further investigation from these preliminary findings may clarify whether NTBI assessment may have a role in evaluating the risks and optimizing treatment for transfusion-dependent patients.

UR - http://www.scopus.com/inward/record.url?scp=58149458142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149458142&partnerID=8YFLogxK

U2 - 10.1002/ajh.21317

DO - 10.1002/ajh.21317

M3 - Article

C2 - 19006228

AN - SCOPUS:58149458142

VL - 84

SP - 29

EP - 33

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -